1	Increased	Increase	B-NP	VBN	O	3	NMOD	17	Increased
2	serum	serum	I-NP	NN	O	3	NMOD	0
3	levels	level	I-NP	NNS	O	0	ROOT	0
4	of	of	B-PP	IN	O	3	NMOD	0
5	vascular	vascular	B-NP	JJ	B-protein	8	NMOD	0
6	endothelial	endothelial	I-NP	JJ	I-protein	8	NMOD	0
7	growth	growth	I-NP	NN	I-protein	8	NMOD	0
8	factor	factor	I-NP	NN	I-protein	4	PMOD	0
9	in	in	B-PP	IN	O	3	NMOD	0
10	patients	patient	B-NP	NNS	O	9	PMOD	0
11	with	with	B-PP	IN	O	10	NMOD	0
12	renal	renal	B-NP	JJ	O	14	NMOD	0
13	cell	cell	I-NP	NN	O	14	NMOD	0
14	carcinoma	carcinoma	I-NP	NN	O	11	PMOD	0
15	.	.	O	.	O	3	P	0

1	Neovascularization	Neovascularization	B-NP	NN	O	5	NMOD	3	Neovascularization
2	,	,	O	,	O	5	P	0
3	an	an	B-NP	DT	O	5	NMOD	0
4	essential	essential	I-NP	JJ	O	5	NMOD	17	essential
5	event	event	I-NP	NN	O	13	SUB	0
6	for	for	B-PP	IN	O	5	NMOD	0
7	the	the	B-NP	DT	O	8	NMOD	0
8	growth	growth	I-NP	NN	O	6	PMOD	4	growth
9	of	of	B-PP	IN	O	8	NMOD	0
10	solid	solid	B-NP	JJ	O	11	NMOD	0
11	tumors	tumor	I-NP	NNS	O	9	PMOD	0
12	,	,	O	,	O	5	P	0
13	is	be	B-VP	VBZ	O	0	ROOT	0
14	regulated	regulate	I-VP	VBN	O	13	VC	16	regulated
15	by	by	B-PP	IN	O	14	VMOD	0
16	a	a	B-NP	DT	O	17	NMOD	0
17	number	number	I-NP	NN	O	15	PMOD	0
18	of	of	B-PP	IN	O	17	NMOD	0
19	angiogenic	angiogenic	B-NP	JJ	B-protein	20	NMOD	3	angiogenic
20	factors	factor	I-NP	NNS	I-protein	18	PMOD	0
21	.	.	O	.	O	13	P	0

1	One	One	B-NP	CD	O	3	NMOD	0
2	such	such	I-NP	JJ	O	3	NMOD	0
3	factor	factor	I-NP	NN	O	8	NMOD	0
4	,	,	O	,	O	8	P	0
5	vascular	vascular	B-NP	JJ	B-protein	8	NMOD	0
6	endothelial	endothelial	I-NP	JJ	I-protein	8	NMOD	0
7	growth	growth	I-NP	NN	I-protein	8	NMOD	0
8	factor	factor	I-NP	NN	I-protein	13	SUB	0
9	(	(	O	(	O	11	DEP	0
10	VEGF	VEGF	B-NP	NN	B-protein	11	DEP	0
11	)	)	O	)	O	8	NMOD	0
12	,	,	O	,	O	8	P	0
13	is	be	B-VP	VBZ	O	0	ROOT	0
14	considered	consider	I-VP	VBN	O	13	VC	0
15	to	to	I-VP	TO	O	16	VMOD	0
16	exert	exert	I-VP	VB	O	14	VMOD	0
17	a	a	B-NP	DT	O	20	NMOD	0
18	potent	potent	I-NP	JJ	O	20	NMOD	0
19	angiogenic	angiogenic	I-NP	JJ	O	20	NMOD	3	angiogenic
20	activity	activity	I-NP	NN	O	16	OBJ	0
21	,	,	O	,	O	14	P	0
22	as	as	B-SBAR	IN	O	14	VMOD	0
23	indicated	indicate	B-VP	VBN	O	22	SBAR	0
24	by	by	B-PP	IN	O	23	VMOD	0
25	immunohistochemical	immunohistochemical	B-NP	JJ	O	28	NMOD	0
26	and	and	I-NP	CC	O	28	NMOD	0
27	molecular	molecular	I-NP	JJ	O	28	NMOD	0
28	evidence	evidence	I-NP	NN	O	24	PMOD	0
29	.	.	O	.	O	13	P	0

1	In	In	B-PP	IN	O	5	VMOD	0
2	this	this	B-NP	DT	O	3	NMOD	0
3	study	study	I-NP	NN	O	1	PMOD	0
4	we	we	B-NP	PRP	O	5	SUB	0
5	investigated	investigate	B-VP	VBD	O	0	ROOT	0
6	the	the	B-NP	DT	O	9	NMOD	0
7	serum	serum	I-NP	NN	O	9	NMOD	0
8	VEGF	VEGF	I-NP	NN	O	9	NMOD	0
9	level	level	I-NP	NN	O	5	OBJ	0
10	(	(	O	(	O	12	DEP	0
11	s-VEGF	s-VEGF	B-NP	NN	O	12	DEP	0
12	)	)	O	)	O	9	NMOD	0
13	in	in	B-PP	IN	O	9	NMOD	0
14	patients	patient	B-NP	NNS	O	13	PMOD	0
15	with	with	B-PP	IN	O	14	NMOD	0
16	renal	renal	B-NP	JJ	O	18	NMOD	0
17	cell	cell	I-NP	NN	O	18	NMOD	0
18	carcinoma	carcinoma	I-NP	NN	O	15	PMOD	0
19	(	(	O	(	O	21	DEP	0
20	RCC	RCC	B-NP	NN	O	21	DEP	0
21	)	)	O	)	O	18	NMOD	0
22	.	.	O	.	O	5	VMOD	0
23	s-VEGF	s-VEGF	B-NP	NN	B-protein	28	SUB	0
24	in	in	B-PP	IN	O	23	NMOD	0
25	peripheral	peripheral	B-NP	JJ	B-cell_type	27	NMOD	0
26	blood	blood	I-NP	NN	I-cell_type	27	NMOD	0
27	samples	sample	I-NP	NNS	I-cell_type	24	PMOD	0
28	was	be	B-VP	VBD	O	22	SBAR	0
29	analyzed	analyze	I-VP	VBN	O	28	VC	0
30	in	in	B-PP	IN	O	29	VMOD	0
31	40	40	B-NP	CD	O	33	NMOD	0
32	RCC	RCC	I-NP	NN	O	33	NMOD	0
33	patients	patient	I-NP	NNS	O	36	NMOD	0
34	and	and	O	CC	O	36	NMOD	0
35	40	40	B-NP	CD	O	36	NMOD	0
36	patients	patient	I-NP	NNS	O	30	PMOD	0
37	without	without	B-PP	IN	O	36	NMOD	0
38	cancer	cancer	B-NP	NN	O	37	PMOD	0
39	(	(	O	(	O	41	DEP	0
40	controls	control	B-NP	NNS	O	41	DEP	0
41	)	)	O	)	O	38	NMOD	0
42	using	use	B-VP	VBG	O	28	VMOD	0
43	a	a	B-NP	DT	O	46	NMOD	0
44	sandwich	sandwich	I-NP	JJ	O	46	NMOD	0
45	enzyme-linked	enzyme-linked	I-NP	JJ	O	46	NMOD	0
46	immunoassay	immunoassay	I-NP	NN	O	42	OBJ	0
47	.	.	O	.	O	5	P	0

1	In	In	B-PP	IN	O	8	VMOD	0
2	20	20	B-NP	CD	O	4	NMOD	0
3	RCC	RCC	I-NP	NN	O	4	NMOD	0
4	patients	patient	I-NP	NNS	O	1	PMOD	0
5	,	,	O	,	O	8	P	0
6	serum	serum	B-NP	NN	O	7	NMOD	0
7	samples	sample	I-NP	NNS	O	8	SUB	0
8	were	be	B-VP	VBD	O	0	ROOT	0
9	obtained	obtain	I-VP	VBN	O	8	VC	0
10	separately	separately	B-ADVP	RB	O	9	VMOD	0
11	from	from	B-PP	IN	O	9	VMOD	0
12	the	the	B-NP	DT	O	15	NMOD	0
13	bilateral	bilateral	I-NP	JJ	O	15	NMOD	0
14	renal	renal	I-NP	JJ	O	15	NMOD	0
15	veins	vein	I-NP	NNS	O	11	PMOD	0
16	.	.	O	.	O	8	P	0

1	s-VEGF	s-VEGF	B-NP	NN	O	2	SUB	0
2	was	be	B-VP	VBD	O	0	ROOT	0
3	also	also	I-VP	RB	O	2	VMOD	0
4	measured	measure	I-VP	VBN	O	2	VC	0
5	before	before	B-ADVP	IN	O	4	VMOD	0
6	,	,	O	,	O	5	P	0
7	4	4	B-NP	CD	O	9	AMOD	0
8	and	and	I-NP	CC	O	9	AMOD	0
9	8	8	I-NP	CD	O	10	NMOD	0
10	weeks	week	I-NP	NNS	O	6	ROOT	0
11	after	after	B-PP	IN	O	10	NMOD	0
12	nephrectomy	nephrectomy	B-NP	NN	O	11	PMOD	0
13	in	in	B-PP	IN	O	12	NMOD	0
14	11	11	B-NP	CD	O	15	NMOD	0
15	patients	patient	I-NP	NNS	O	13	PMOD	0
16	.	.	O	.	O	10	P	0

1	There	There	B-NP	EX	O	2	SUB	0
2	were	be	B-VP	VBD	O	0	ROOT	0
3	significant	significant	B-NP	JJ	O	4	NMOD	0
4	differences	difference	I-NP	NNS	O	2	PRD	0
5	in	in	B-PP	IN	O	4	NMOD	0
6	s-VEGF	s-VEGF	B-NP	NN	O	5	PMOD	0
7	between	between	B-PP	IN	O	6	NMOD	0
8	the	the	B-NP	DT	O	10	NMOD	0
9	RCC	RCC	I-NP	NN	O	10	NMOD	0
10	patients	patient	I-NP	NNS	O	13	NMOD	0
11	and	and	O	CC	O	13	NMOD	0
12	the	the	B-NP	DT	O	13	NMOD	0
13	controls	control	I-NP	NNS	O	7	PMOD	0
14	(	(	O	(	O	21	DEP	0
15	207.3+/-32.9	207.3+/-32.9	B-NP	CD	O	18	NMOD	0
16	vs.	vs.	I-NP	IN	O	18	NMOD	0
17	71.5+/-9.1	71.5+/-9.1	B-NP	CD	O	18	NMOD	0
18	pg/ml	pg/ml	I-NP	NN	O	20	NMOD	0
19	,	,	O	,	O	20	P	0
20	mean+/-SE	mean+/-SE	B-NP	NN	O	21	DEP	0
21	)	)	O	)	O	13	NMOD	0
22	(	(	O	(	O	27	DEP	0
23	P	P	B-NP	NN	O	25	SUB	0
24	less	less	B-ADJP	JJR	O	25	AMOD	0
25	than	than	B-PP	IN	O	27	DEP	0
26	0.005	0.005	B-NP	CD	O	25	AMOD	0
27	)	)	O	)	O	13	NMOD	0
28	,	,	O	,	O	2	P	0
29	between	between	B-PP	IN	O	2	VMOD	0
30	the	the	B-NP	DT	O	33	NMOD	0
31	tumor-bearing	tumor-bearing	I-NP	JJ	O	33	NMOD	0
32	renal	renal	I-NP	JJ	O	33	NMOD	0
33	veins	vein	I-NP	NNS	O	37	NMOD	0
34	and	and	O	CC	O	37	NMOD	0
35	the	the	B-NP	DT	O	37	NMOD	0
36	contralateral	contralateral	I-NP	JJ	O	37	NMOD	0
37	ones	one	I-NP	NNS	O	29	PMOD	0
38	(	(	O	(	O	43	DEP	0
39	P	P	B-NP	NN	O	41	SUB	0
40	less	less	B-ADJP	JJR	O	41	AMOD	0
41	than	than	B-PP	IN	O	43	DEP	0
42	0.01	0.01	B-NP	CD	O	41	AMOD	0
43	)	)	O	)	O	37	NMOD	0
44	,	,	O	,	O	2	P	0
45	between	between	B-PP	IN	O	2	VMOD	0
46	the	the	B-NP	DT	O	50	NMOD	0
47	pre-	pre-	I-NP	JJ	O	50	NMOD	0
48	and	and	I-NP	CC	O	50	NMOD	0
49	post-nephrectomy	post-nephrectomy	I-NP	JJ	O	50	NMOD	0
50	situations	situation	I-NP	NNS	O	45	PMOD	0
51	(	(	O	(	O	56	DEP	0
52	P	P	B-NP	NN	O	54	SUB	0
53	less	less	B-ADJP	JJR	O	54	AMOD	0
54	than	than	B-PP	IN	O	56	DEP	0
55	0.01	0.01	B-NP	CD	O	54	AMOD	0
56	)	)	O	)	O	50	NMOD	0
57	and	and	O	CC	O	45	PMOD	0
58	among	among	B-PP	IN	O	45	PMOD	0
59	the	the	B-NP	DT	O	61	NMOD	0
60	various	various	I-NP	JJ	O	61	NMOD	0
61	parameters	parameter	I-NP	NNS	O	58	PMOD	0
62	of	of	B-PP	IN	O	61	NMOD	0
63	tumor	tumor	B-NP	NN	O	64	NMOD	0
64	status	status	I-NP	NN	O	62	PMOD	0
65	such	such	B-PP	JJ	O	58	PMOD	0
66	as	as	I-PP	IN	O	45	PMOD	0
67	tumor	tumor	B-NP	NN	O	68	NMOD	0
68	extent	extent	I-NP	NN	O	76	NMOD	0
69	(	(	O	(	O	74	DEP	0
70	P	P	B-NP	NN	O	74	DEP	0
71	less	less	B-ADJP	JJR	O	70	NMOD	0
72	than	than	B-PP	IN	O	71	AMOD	0
73	0.001	0.001	B-NP	CD	O	72	PMOD	0
74	)	)	O	)	O	68	NMOD	0
75	and	and	O	CC	O	76	NMOD	0
76	existence	existence	B-NP	NN	O	66	PMOD	0
77	of	of	B-PP	IN	O	76	NMOD	0
78	metastasis	metastasis	B-NP	NN	O	77	PMOD	0
79	(	(	O	(	O	84	DEP	0
80	P	P	B-NP	NN	O	84	DEP	0
81	less	less	B-ADJP	JJR	O	80	NMOD	0
82	than	than	B-PP	IN	O	81	AMOD	0
83	0.001	0.001	B-NP	CD	O	82	PMOD	0
84	)	)	O	)	O	78	NMOD	0
85	.	.	O	.	O	2	P	0

1	s-VEGF	s-VEGF	B-NP	NN	O	3	SUB	0
2	significantly	significantly	B-ADVP	RB	O	3	VMOD	0
3	correlated	correlate	B-VP	VBD	O	0	ROOT	0
4	with	with	B-PP	IN	O	3	VMOD	0
5	the	the	B-NP	DT	O	7	NMOD	0
6	tumor	tumor	I-NP	NN	O	7	NMOD	0
7	volume	volume	I-NP	NN	O	4	PMOD	0
8	obtained	obtain	B-VP	VBN	O	7	NMOD	0
9	by	by	B-PP	IN	O	8	VMOD	0
10	a	a	B-NP	DT	O	12	NMOD	0
11	three-dimensional	three-dimensional	I-NP	JJ	O	12	NMOD	0
12	measurement	measurement	I-NP	NN	O	9	PMOD	0
13	(	(	O	(	O	20	DEP	0
14	r=0.802	r=0.802	B-NP	NN	O	16	NMOD	0
15	,	,	O	,	O	16	P	0
16	P	P	B-NP	NN	O	20	DEP	0
17	less	less	B-ADJP	JJR	O	16	NMOD	0
18	than	than	B-PP	IN	O	17	AMOD	0
19	0.0001	0.0001	B-NP	CD	O	18	PMOD	0
20	)	)	O	)	O	12	NMOD	0
21	.	.	O	.	O	3	P	0

1	The	The	B-NP	DT	O	4	NMOD	0
2	sensitivity	sensitivity	I-NP	NN	O	4	NMOD	0
3	and	and	I-NP	CC	O	4	NMOD	0
4	specificity	specificity	I-NP	NN	O	22	SUB	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	s-VEGF	s-VEGF	B-NP	NN	B-protein	5	PMOD	0
7	at	at	B-PP	IN	O	4	NMOD	0
8	the	the	B-NP	DT	O	10	NMOD	0
9	cut-off	cut-off	I-NP	JJ	O	10	NMOD	0
10	level	level	I-NP	NN	O	7	PMOD	0
11	of	of	B-PP	IN	O	10	NMOD	0
12	100	100	B-NP	CD	O	13	NMOD	0
13	pg/ml	pg/ml	I-NP	NN	O	11	PMOD	0
14	,	,	O	,	O	4	P	0
15	as	as	B-SBAR	IN	O	4	NMOD	0
16	determined	determine	B-VP	VBN	O	15	SBAR	0
17	by	by	B-PP	IN	O	16	VMOD	0
18	the	the	B-NP	DT	O	20	NMOD	0
19	receiver-operating-characteristics	receiver-operating-characteristic	I-NP	NNS	O	20	NMOD	0
20	curve	curve	I-NP	NN	O	17	PMOD	0
21	,	,	O	,	O	4	P	0
22	were	be	B-VP	VBD	O	0	ROOT	0
23	80.0	80.0	B-NP	CD	O	24	NMOD	0
24	%	%	I-NP	NN	O	27	NMOD	0
25	and	and	O	CC	O	27	NMOD	0
26	72.5	72.5	B-NP	CD	O	27	NMOD	0
27	%	%	I-NP	NN	O	22	PRD	0
28	,	,	O	,	O	22	P	0
29	respectively	respectively	B-ADVP	RB	O	22	VMOD	0
30	.	.	O	.	O	22	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	results	result	I-NP	NNS	O	3	SUB	0
3	indicate	indicate	B-VP	VBP	O	0	ROOT	0
4	that	that	B-SBAR	IN	O	17	DEP	0
5	tumor	tumor	B-NP	NN	O	6	NMOD	0
6	tissue	tissue	I-NP	NN	O	9	SUB	0
7	of	of	B-PP	IN	O	6	NMOD	0
8	RCC	RCC	B-NP	NN	O	7	PMOD	0
9	liberates	liberate	B-VP	VBZ	O	4	SBAR	14	liberates
10	VEGF	VEGF	B-NP	NN	B-protein	9	OBJ	0
11	into	into	B-PP	IN	O	9	VMOD	0
12	the	the	B-NP	DT	O	15	NMOD	0
13	systemic	systemic	I-NP	JJ	O	15	NMOD	0
14	blood	blood	I-NP	NN	O	15	NMOD	0
15	flow	flow	I-NP	NN	O	11	PMOD	0
16	and	and	O	CC	O	17	DEP	0
17	that	that	B-SBAR	IN	O	3	VMOD	0
18	s-VEGF	s-VEGF	B-NP	NN	B-protein	19	SUB	0
19	is	be	B-VP	VBZ	O	17	SBAR	0
20	a	a	B-NP	DT	O	22	NMOD	0
21	possible	possible	I-NP	JJ	O	22	NMOD	0
22	marker	marker	I-NP	NN	O	19	PRD	0
23	for	for	B-PP	IN	O	22	NMOD	0
24	RCC	RCC	B-NP	NN	O	23	PMOD	0
25	.	.	O	.	O	3	P	0

